173 related articles for article (PubMed ID: 38750699)
21. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?
Kobayashi H; Watanabe R; Choyke PL
Theranostics; 2013 Dec; 4(1):81-9. PubMed ID: 24396516
[TBL] [Abstract][Full Text] [Related]
22. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
Islam W; Fang J; Imamura T; Etrych T; Subr V; Ulbrich K; Maeda H
Mol Cancer Ther; 2018 Dec; 17(12):2643-2653. PubMed ID: 30232144
[TBL] [Abstract][Full Text] [Related]
23. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
24. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
Li L; ten Hagen TL; Hossann M; Süss R; van Rhoon GC; Eggermont AM; Haemmerich D; Koning GA
J Control Release; 2013 Jun; 168(2):142-50. PubMed ID: 23524188
[TBL] [Abstract][Full Text] [Related]
25. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
26. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
[TBL] [Abstract][Full Text] [Related]
27. A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
Li L; ten Hagen TL; Haeri A; Soullié T; Scholten C; Seynhaeve AL; Eggermont AM; Koning GA
J Control Release; 2014 Jan; 174():202-8. PubMed ID: 24269966
[TBL] [Abstract][Full Text] [Related]
28. Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors.
Islam R; Maeda H; Fang J
Expert Opin Drug Deliv; 2022 Feb; 19(2):199-212. PubMed ID: 33430661
[TBL] [Abstract][Full Text] [Related]
29. Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.
Centelles MN; Wright M; So PW; Amrahli M; Xu XY; Stebbing J; Miller AD; Gedroyc W; Thanou M
J Control Release; 2018 Jun; 280():87-98. PubMed ID: 29723616
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticle-mediated internal radioisotope therapy to locally increase the tumor vasculature permeability for synergistically improved cancer therapies.
Liang C; Chao Y; Yi X; Xu J; Feng L; Zhao Q; Yang K; Liu Z
Biomaterials; 2019 Mar; 197():368-379. PubMed ID: 30703742
[TBL] [Abstract][Full Text] [Related]
31. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
Dhaliwal A; Zheng G
Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
[TBL] [Abstract][Full Text] [Related]
32. An implantable smart magnetic nanofiber device for endoscopic hyperthermia treatment and tumor-triggered controlled drug release.
Sasikala ARK; Unnithan AR; Yun YH; Park CH; Kim CS
Acta Biomater; 2016 Feb; 31():122-133. PubMed ID: 26687978
[TBL] [Abstract][Full Text] [Related]
33. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
34. Targeting endothelial permeability in the EPR effect.
Lahooti B; Akwii RG; Zahra FT; Sajib MS; Lamprou M; Alobaida A; Lionakis MS; Mattheolabakis G; Mikelis CM
J Control Release; 2023 Sep; 361():212-235. PubMed ID: 37517543
[TBL] [Abstract][Full Text] [Related]
35. Biological rationales and clinical applications of temperature controlled hyperthermia--implications for multimodal cancer treatments.
Schildkopf P; Ott OJ; Frey B; Wadepohl M; Sauer R; Fietkau R; Gaipl US
Curr Med Chem; 2010; 17(27):3045-57. PubMed ID: 20629627
[TBL] [Abstract][Full Text] [Related]
36. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
37. Tumor vascular permeabilization using localized mild hyperthermia to improve macromolecule transport.
Kirui DK; Koay EJ; Guo X; Cristini V; Shen H; Ferrari M
Nanomedicine; 2014 Oct; 10(7):1487-96. PubMed ID: 24262998
[TBL] [Abstract][Full Text] [Related]
38. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
Acharya S; Sahoo SK
Adv Drug Deliv Rev; 2011 Mar; 63(3):170-83. PubMed ID: 20965219
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
Frazier N; Ghandehari H
Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
[TBL] [Abstract][Full Text] [Related]
40. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors.
Willerding L; Limmer S; Hossann M; Zengerle A; Wachholz K; Ten Hagen TL; Koning GA; Sroka R; Lindner LH; Peller M
J Control Release; 2016 Jan; 222():47-55. PubMed ID: 26658073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
